Tadalafil as Adjuvant Therapy for DMD

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

September 5, 2025

Study Completion Date

September 5, 2025

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Tadalafil

Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (MRI, exercise testing, clinical function) will be performed 3 hours after time of dosing.

DRUG

Tadalafil

Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (Doppler US, exercise testing, clinical function) will be performed 3 hours after time of dosing.

Trial Locations (1)

32610

University of Florida, Gainesville

All Listed Sponsors
lead

University of Florida

OTHER